Literature Scan

New and noteworthy research from the medial literature landscape.

  • Lenalidomide Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults Tuesday, February 14th, 2017 | March 2017, Volume 3, Issue 4

    Results from the Myeloma XI trial presented at the 2016 ASH Annual Meeting supported the use of lenalidomide as maintenance therapy for patients with newly diagnosed, symptomatic multiple myeloma (MM), as it extended progression-free survival without significant increases in toxicity. However, a new analysis from the trial, published in the Blood Cancer Journal, raises questions […]

  • Severe Fatigue Affects Survival and Social Reintegration for Hodgkin Lymphoma Survivors Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Approximately 40 percent of patients with Hodgkin lymphoma (HL) experience persistent fatigue, a chronic symptom that can affect patients years after successful treatment. In a large, prospective study published in the Journal of Clinical Oncology, researchers characterized fatigue and its effects on the daily lives of nearly 4,000 patients with HL, finding that baseline severe […]

  • Is It Safe to Eliminate CHOP Consolidation Therapy for Patients With CD20+ Post-Transplant Lymphoproliferative Disorders? Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Results from the phase II PTLD-1 (Sequential Treatment of CD20-Positive Post-Transplant Lymphoproliferative Disorder) trial established sequential treatment with four cycles of weekly rituximab followed by four cycles of chemotherapy with CHOP-21 (cyclophosphamide, doxorubicin, vincristine, and prednisone every 21 days) as a standard regimen for patients with post-transplant lymphoproliferative disorders (PTLDs). However, in a recent study […]

  • Enoxaparin Does Not Prevent Placenta-Mediated Complications in Pregnant Women With Severe Preeclampsia Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Pregnant women who have severe preeclampsia (a disease characterized by impaired vascular response to placentation) before 34 weeks of pregnancy are at an increased risk for severe maternal and perinatal complications, including a higher risk of developing eclampsia during subsequent pregnancies and a lower-than-average birthweight. Though research has suggested that prophylactic doses of low-molecular-weight heparin […]

  • Randomized Trial Finds Rivaroxaban a Safer Option Than Warfarin for Patients With Atrial Fibrillation Undergoing PCI Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    The “triple-therapy” anticoagulation regimen (consisting of a vitamin K antagonist [VKA] plus dual antiplatelet therapy [DAPT] with a P2Y12 inhibitor and aspirin) has been shown to reduce thrombotic and stroke risk in patients with atrial fibrillation (AF) undergoing percutaneous intervention (PCI) with stent placement. However, this regimen does increase bleeding risk. According to results from […]

1 of 22
back to top